McKesson Corporation vs Rivian Automotive, Inc. — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Rivian Automotive, Inc. trades at $13.99 (market cap $20.75B). The key difference: McKesson Corporation is far larger — about 5.2× Rivian Automotive, Inc.'s market cap, and McKesson Corporation pays a 0.4% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Rivian Automotive, Inc. for 61 Days on average.
| MCK | RIVN | |
|---|---|---|
Market Cap | $108.46B | $20.75B |
Volume | 712,607 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $22.45 |
52-Week Low | $725.17 | $12.50 |
Typical Hold Time | 74 Days | 61 Days |
Enterprise Value | $115.00B | $20.79B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Rivian Automotive (RIVN) trades at $13.96, down 2.65% amid bearish technical signals despite strong Q3 2026 delivery results. The company reported record production of 19,751 vehicles and deliveries of 19,248, beating estimates but maintaining unchanged guidance. Fundamentally, RIVN shows improving revenue growth ($5.39B in 2025) but continues significant losses (-$3.65B net income) with negative margins. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show 18 sell signals versus 2 buy signals.
Rivian's investment case balances strong delivery growth and R2 SUV ramp-up against persistent cash burn and competitive EV market pressures. The stock offers upside to analyst targets but faces execution risks in achieving profitability. Key catalysts include R2 production scaling and autonomy technology rollout, while main risks involve cash flow sustainability and intense industry competition.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →